Search | Clinical Trials Finder

Conditions: Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions: esomeprazole magnesium (oral medication); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 39
States / cities: Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more

Conditions: Healthy Volunteers
Interventions: TAK-906, Esomeprazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Heartburn
Interventions: Esomeprazole magnesium (Nexium); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 26
States / cities: Tucson, Arizona • Anaheim, California • Orange, California + 23 more

Conditions: Healthy
Interventions: Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Reflux, Esophagitis, Barrett's Esophagus
Interventions: Esomeprazole (Nexium) 40 mg/day; Drug
Lead sponsor: Main Line Health; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Asthma, Lung Diseases, Lung Diseases, Obstructive
Interventions: Esomeprazole, Placebo proton pump inhibitor; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more

Conditions: Gastroesophageal Reflux Disease
Interventions: esomeprazole; Drug
Lead sponsor: Southern Arizona VA Health Care System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Familial Hypercholesterolemia
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more

Conditions: Healthy Volunteers
Interventions: Aspirin, Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Autism, Autism Spectrum Disorder
Interventions: Esomeprazole; Drug
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 6 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cystic Fibrosis
Interventions: Esomeprazole, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: BMS-986278 Tablet, Esomeprazole, BMS-986278 suspension; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Gastroesophageal Reflux Disease
Interventions: arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 62
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more

Conditions: Healthy Participants
Interventions: Emraclidine, Esomeprazole; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Cancer
Interventions: Oral Taxane; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Timeline: Started 2006
U.S. locations: 3
States / cities: Newark, Delaware • Louisville, Kentucky • Las Vegas, Nevada

Conditions: Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
Interventions: Secretol, Nexium; Drug
Lead sponsor: Effexus Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Dysphagia, GERD, Degenerative Joint Disease
Interventions: Esomeprazole, Placebo Oral Tablet; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Anastomotic Stricture, Morbid Obesity
Interventions: Esomeprazole; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pharmacokinetics
Interventions: esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Up to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Park Ridge, Illinois + 8 more

Conditions: Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions: Esomeprazole (Nexium); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 24
States / cities: Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more

Conditions: GERD
Interventions: esomeprazole 40 mg; Drug
Lead sponsor: David A. Johnson, MD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Heartburn
Interventions: Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: GERD
Interventions: Antacids; Drug
Lead sponsor: Digestive & Liver Disease Specialists; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Nausea
Interventions: esomeprazole, Placebo; Drug · Other
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

The Effect of Nexium on Transmucosal Esophageal Leak

Study of Acid Reflux in Asthma

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin

Study to Evaluate the Interaction Between Aspirin and Nexium

A Study of Esomeprazole in Children With Autism

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery

Phase 1 Pharmacokinetics of Intravenous Nexium in Children

Esomeprazole for Treatment of GERD in Pediatric Patients

Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

Nexium Study To Suppress Nausea During Chemotherapy